Voyager Therapeutics (VYGR) Current Assets (2014 - 2026)

Voyager Therapeutics has disclosed Current Assets across 13 years of filings, most recently posting $147.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $147.0 million, down 40.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $147.0 million (down 40.06% YoY), and the FY2025 annual result was $202.7 million, down 26.78% from the prior year.
• Current Assets came in at $147.0 million for Q1 2026 at Voyager Therapeutics, down from $202.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $409.1 million in Q1 2024 to a low of $124.5 million in Q4 2022.
• The 5-year median for Current Assets is $245.2 million (2025), against an average of $249.6 million.
• Across the five-year window, Current Assets soared 156.78% in 2023 and tumbled 41.2% in 2025, its largest moves.
• Voyager Therapeutics' Current Assets stood at $124.5 million in 2022, then surged by 156.78% to $319.7 million in 2023, then dropped by 13.41% to $276.8 million in 2024, then slipped by 26.78% to $202.7 million in 2025, then retreated by 27.48% to $147.0 million in 2026.
• The last three Current Assets figures came in at $147.0 million (Q1 2026), $202.7 million (Q4 2025), and $219.6 million (Q3 2025), per Business Quant data.